Welcome to BioMS Medical
BioMS Medical is a Canadian biotechnology company engaged in the development and commercialization of novel therapeutic technologies with emphasis on the treatment of multiple sclerosis (MS).
Global Trials
BioMS Medical is currently conducting late-stage clinical trials for its lead drug, dirucotide (MBP8298), for the treatment of multiple sclerosis.
- MAESTRO-01 (phase III Canadian and European trial for the treatment of Secondary Progressive Multiple Sclerosis)
- MAESTRO-02 (open-label, follow-on Multiple Sclerosis trial for MAESTRO-01)
- MAESTRO-03 (phase III U.S. trial for the treatment of Secondary Progressive Multiple Sclerosis)
- MINDSET-01 (phase II Relapsing Remitting Multiple Sclerosis trial)